Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (760)	5/7/1998 12:21:00 PM
From: David Israel-Rosen	Read Replies (1) \| Respond to of 1491

Management is listening to share holders: Thursday May 7, 11:50 am Eastern Time Company Press Release SOURCE: Pharmos Corporation Pharmos Corporation Product Development Update ISELIN, N.J., May 7 /PRNewswire/ -- Pharmos Corporation (Nasdaq: PARS - news) announced that Lotemax(TM) and Alrex(TM), products co-developed and marketed by Bausch & Lomb Pharmaceuticals, Inc. (NYSE: BOL - news), will available by prescription on June 1. Pharmos Corporation recently completed enrollment of severe head trauma patients treated with the second dose (150 mg) of dexanabinol (HU-211) in its Phase II clinical trial and began enrolling patients to be treated with the third dose (300 mg). Sixty-seven patients have been enrolled so far with no apparent safety concerns (an external safety committee is monitoring the study). The overall mortality in the study is about 12%, a low percentage based on the patient population which consists of severe head trauma patients with Glasgow Coma Scores between 4 and 8. The company is planning to unblind the first two dosages (50 mg and 150 mg) this summer. The information will help with the planning of Phase III clinical trial in head trauma, Phase II in stroke, and in negotiations with strategic partners. The company is continuing the development of its tamoxifen analog program. In pre-clinical studies one analog, tamoxifen methiodide (TMI) has expressed higher tumorcidal activity compared to tamoxifen. The results may be due to TMI's mechanism of action including its anti-angiogenic activity. TMI also demonstrated a much better safety profile than the base tamoxifen used in the National Cancer Institute study. Pharmos plans to complete the pre-clinical development of this analog toward the end of 1998. Pharmos Corporation ( pharmoscorp.com ) is a pharmaceutical company specializing in the modification of existing molecules to improve their therapeutic index, i.e. reduce undesirable side effects and/or enhance efficacy. This news release contains forward-looking statements that involve risk and uncertainties. The development of the company's products may differ materially from the company's expectations. Among the factors that could result in a materially different outcome are the inherent uncertainties accompanying new product development, action of regulatory authorities and the results of further trials. SOURCE: Pharmos Corporation

To: David Israel-Rosen who wrote (760)	5/7/1998 12:36:00 PM
From: Omer Shvili	Respond to of 1491

Dear David: I completely agree with you. PARS' management team is highly competent, and I'm sure that with time the market will understand what this company is really worth. Maybe when analysts stop following search engines (and give them valuations of billions), and start to follow real companies, this will happen. Pharmos' management is very conservative, and that is an asset to us, as we can buy shares at these ridiculously low prices (and we can be sure it isn't hyped). To answer arnie's questions from a couple of posts back. I too am not happy with the private placements which took place, but PARS didn't have much choice (it's not like they had H&Q at their feet). During the time of the placements, the company had no FDA approval and was running out of cash, and so it had to go to people like Castle Creek. If the company will need to raise money in the future, you can bet it won't be from those hedge funds. Currently, PARS has two approved drugs (with the third - LE-T - on the way), it's not far from becoming profitable and it has a very promising pipeline. With such a background (especially the fact that we have revenues), Merrill Lynch and their buddies would love to help us raise money. Omer